NAFL
MCID: NNL005
MIFTS: 63

Non-Alcoholic Fatty Liver Disease (NAFL)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Non-Alcoholic Fatty Liver Disease

MalaCards integrated aliases for Non-Alcoholic Fatty Liver Disease:

Name: Non-Alcoholic Fatty Liver Disease 12 43 15 17 70
Nonalcoholic Fatty Liver Disease 43 36 15
Non-Alcoholic Fatty Liver 12 15 17
Steatosis 43 6 17
Nonalcoholic Steatohepatitis 43 70
Fatty Liver 43 70
Nafld 12 43
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 43
Fatty Degeneration 70
Steatohepatitis 70
Nafl 12
Nash 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0080208 DOID:0080546
KEGG 36 H01333
UMLS 70 C0015695 C0152254 C0400966 more

Summaries for Non-Alcoholic Fatty Liver Disease

MedlinePlus Genetics : 43 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged.Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding.NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer).NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.

MalaCards based summary : Non-Alcoholic Fatty Liver Disease, also known as nonalcoholic fatty liver disease, is related to non-alcoholic steatohepatitis and body mass index quantitative trait locus 11. An important gene associated with Non-Alcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease and Glycerolipid metabolism. The drugs Milk thistle and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, eye and kidney.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is not caused by heavy alcohol use.

KEGG : 36 It has been reported that those patients with nonalcoholic fatty liver disease (NAFLD) are probably more common in those individuals with metabolic syndrome, which includes obesity and type 2 diabetes mellitus. The spectrum of NAFLD ranges from simple steatosis to steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). Of those with NASH, approximately 20% will go on to develop cirrhosis and hepatocellular carcinoma.

Related Diseases for Non-Alcoholic Fatty Liver Disease

Diseases related to Non-Alcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 941)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic steatohepatitis 33.5 MIR34A MIR21 MIR122
2 body mass index quantitative trait locus 11 32.1 PRMT7 MIR378A MIR34A MIR30A MIR27B MIR27A
3 hepatocellular carcinoma 31.6 MIR34A MIR30A MIR27A MIR26A1 MIR22 MIR21
4 lipoprotein quantitative trait locus 31.5 MIR34A MIR27A MIR22 MIR21 MIR140
5 arteries, anomalies of 31.4 MIR34A MIR33A MIR30A MIR27B MIR27A MIR22
6 overnutrition 31.3 MIR378A MIR34A MIR30A MIR27B MIR27A MIR22
7 immune deficiency disease 31.1 MIR34A MIR27A MIR22 MIR21 MIR140 MIR132
8 peripheral nervous system disease 31.0 MIR34A MIR27A MIR22 MIR21 MIR122
9 disease by infectious agent 30.9 MIR34A MIR30A MIR27B MIR27A MIR22 MIR21
10 inherited metabolic disorder 30.9 MIR34A MIR30A MIR21 MIR122
11 acquired metabolic disease 30.7 MIR378A MIR34A MIR30A MIR27B MIR27A MIR22
12 renal fibrosis 30.6 MIR21 MIR200B MIR130A
13 biliary tract disease 30.6 MIR378A MIR30A MIR140
14 myeloma, multiple 30.5 MIR30A MIR27A MIR26A1 MIR21 MIR140
15 pulmonary fibrosis, idiopathic 30.5 MIR30A MIR21 MIR140 MIR130A
16 leukemia, acute lymphoblastic 30.5 MIR27B MIR27A MIR22 MIR21 MIR130A
17 gastric cancer 30.5 MIR34A MIR27B MIR27A MIR22 MIR21 MIR140
18 lipid storage disease 30.4 MIR27B MIR22 MIR21 MIR122
19 glucose metabolism disease 30.4 MIR378A MIR30A MIR27A MIR22 MIR21 MIR140
20 intestinal disease 30.4 MIR378A MIR34A MIR30A MIR27B MIR27A MIR26A1
21 bile duct adenocarcinoma 30.3 MIR30A MIR21 MIR140
22 connective tissue disease 30.3 MIR34A MIR30A MIR27A MIR22 MIR21 MIR200B
23 muscular dystrophy, duchenne type 30.2 MIR34A MIR30A MIR22 MIR21 MIR130A
24 kidney cancer 30.2 MIR378A MIR27A MIR21 MIR200B MIR122
25 lymphoma, hodgkin, classic 30.2 MIR30A MIR21 MIR200A MIR140
26 lymphoma, non-hodgkin, familial 30.2 MIR34A MIR30A MIR27A MIR21 MIR200B MIR140
27 ovarian disease 30.2 MIR30A MIR27A MIR22 MIR21 MIR200B MIR200A
28 cardiovascular system disease 30.2 MIR34A MIR30A MIR27A MIR21
29 prostate disease 30.1 MIR34A MIR30A MIR27A MIR22 MIR21 MIR200B
30 esophageal cancer 30.0 MIR34A MIR30A MIR21 MIR200A MIR140 MIR10B
31 disease of mental health 29.9 MIR378A MIR34A MIR30A MIR22 MIR21 MIR200A
32 lung cancer 29.9 MIR34A MIR33A MIR30A MIR27B MIR27A MIR26A1
33 pancreas disease 29.7 MIR34A MIR33A MIR30A MIR27B MIR27A MIR22
34 ovarian cancer 29.7 MIR34A MIR30A MIR27A MIR22 MIR21 MIR200B
35 glioblastoma 29.7 MIR34A MIR21 MIR132 MIR130A MIR10B
36 gastrointestinal system disease 29.6 MIR378A MIR34A MIR30A MIR27B MIR27A MIR26A1
37 liver disease 11.9
38 fatty liver disease 11.9
39 fatty liver disease, nonalcoholic 1 11.9
40 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 11.7
41 fatty liver disease, nonalcoholic 2 11.4
42 hypertriglyceridemia, transient infantile 11.4
43 fibrosis of extraocular muscles, congenital, 1 11.3
44 lipid metabolism disorder 11.3
45 lipodystrophy, familial partial, type 2 11.3
46 type 2 diabetes mellitus 11.2
47 reye syndrome 11.2
48 diabetes mellitus 11.1
49 body mass index quantitative trait locus 9 11.1
50 body mass index quantitative trait locus 8 11.1

Graphical network of the top 20 diseases related to Non-Alcoholic Fatty Liver Disease:



Diseases related to Non-Alcoholic Fatty Liver Disease

Symptoms & Phenotypes for Non-Alcoholic Fatty Liver Disease

Drugs & Therapeutics for Non-Alcoholic Fatty Liver Disease

Drugs for Non-Alcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 410)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
2
Atorvastatin Approved Phase 4 134523-00-5 60823
3
Losartan Approved Phase 4 114798-26-4 3961
4
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
5
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
6
Amlodipine Approved Phase 4 88150-42-9 2162
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Glimepiride Approved Phase 4 93479-97-1 3476
9
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
10
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
11
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
12
Ezetimibe Approved Phase 4 163222-33-1 150311
13
Empagliflozin Approved Phase 4 864070-44-0
14
Liraglutide Approved Phase 4 204656-20-2 44147092
15
Insulin aspart Approved Phase 4 116094-23-6 16132418
16
Insulin detemir Approved Phase 4 169148-63-4 5311023
17
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
18
Glucagon Approved Phase 4 16941-32-5
19
Gliclazide Approved Phase 4 21187-98-4 3475
20
Phentermine Approved, Illicit Phase 4 122-09-8 4771
21
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
22
Polyestradiol phosphate Approved Phase 4 28014-46-2
23
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
24
Alogliptin Approved Phase 4 850649-61-5 11450633
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
27
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
28
Methyltestosterone Approved Phase 4 58-18-4 6010
29
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
30
Testosterone enanthate Approved Phase 4 315-37-7 9416
31
Testosterone Approved, Investigational Phase 4 58-22-0 6013
32
Tocopherol Approved, Investigational Phase 4 1406-66-2
33
Dulaglutide Approved, Investigational Phase 4 923950-08-7
34
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
35
Zinc Approved, Investigational Phase 4 7440-66-6 32051
36
Metformin Approved Phase 4 657-24-9 14219 4091
37
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
38
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
39
Insulin glargine Approved Phase 4 160337-95-1
40
Ribavirin Approved Phase 4 36791-04-5 37542
41
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
42
Saxagliptin Approved Phase 4 361442-04-8 11243969
43
Aminolevulinic acid Approved Phase 4 106-60-5 137
44
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
45
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
47
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
48
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
50
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205

Interventional clinical trials:

(show top 50) (show all 1126)
# Name Status NCT ID Phase Drugs
1 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
2 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
3 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Unknown status NCT02649465 Phase 4 Tofogliflozin;Glimepiride
6 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
7 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
8 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
9 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
10 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
11 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
14 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
15 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
16 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
17 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
18 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
19 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
20 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
21 Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Completed NCT04537780 Phase 4 Montelukast
22 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
23 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
24 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
25 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
26 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
27 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
28 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
29 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
30 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
31 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
32 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
33 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
34 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
35 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease:an Multicenter,Randomized, Double-blind, Parallel- Controlled Study. Completed NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
36 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
37 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Completed NCT03849729 Phase 4 Phentermine
38 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
39 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
40 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
41 A 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patients With Uncontrolled Type 2 Diabetes Mellitus. Completed NCT03007329 Phase 4 Exenatide;Exenatide matching Placebo;Dapagliflozin
42 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
43 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
44 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
45 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
46 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
47 Effect of Polydeoxyribonucleotide (PDRN) on Healing and Fatty Degeneration of Rotator Cuff in Human Recruiting NCT03916198 Phase 4 Polydeoxyribonucleotides;Normal saline
48 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
49 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
50 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine

Search NIH Clinical Center for Non-Alcoholic Fatty Liver Disease

Genetic Tests for Non-Alcoholic Fatty Liver Disease

Anatomical Context for Non-Alcoholic Fatty Liver Disease

MalaCards organs/tissues related to Non-Alcoholic Fatty Liver Disease:

40
Liver, Eye, Kidney, Endothelial, Adipocyte, Ovary, Thyroid

Publications for Non-Alcoholic Fatty Liver Disease

Articles related to Non-Alcoholic Fatty Liver Disease:

(show top 50) (show all 28686)
# Title Authors PMID Year
1
An Expanded Multi-Organ Disease Phenotype Associated with Mutations in YARS. 6
29232904 2017
2
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. 47 61
20497147 2010
3
Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. 47 61
19780876 2010
4
Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. 47
20956972 2011
5
Swertiamarin supplementation prevents obesity-related chronic inflammation and insulin resistance in mice fed a high-fat diet. 61
33794740 2021
6
Dysfunctional adiposity index as a marker of adipose tissue morpho-functional abnormalities and metabolic disorders in apparently healthy subjects. 61
33722154 2021
7
Temperature-corrected proton density fat fraction estimation using chemical shift-encoded MRI in phantoms. 61
33565112 2021
8
Physicochemical and histochemical characteristics of bovine longissimus lumborum muscle defected as muscular steatosis (massive adipocyte infiltration). 61
33578246 2021
9
Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis. 61
33184849 2021
10
Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases. 61
33303715 2021
11
Exercise improves lipid droplet metabolism disorder through activation of AMPK-mediated lipophagy in NAFLD. 61
33667513 2021
12
Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. 61
33171266 2021
13
SLC6A14 deficiency is linked to obesity, fatty liver, and metabolic syndrome but only under conditions of a high-fat diet. 61
33513428 2021
14
Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2. 61
33581653 2021
15
Evaluation of hepatic steatosis before liver transplantation in ex vivo by volumetric quantitative PDFF-MRI. 61
33197060 2021
16
Chronic systemic exposure to IL6 leads to deregulation of glycolysis and fat accumulation in the zebrafish liver. 61
33582286 2021
17
Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. 61
33639194 2021
18
Deletion of phospholipase D1 decreases bone mass and increases fat mass via modulation of Runx2, β-catenin-osteoprotegerin, PPAR-γ and C/EBPα signaling axis. 61
33497821 2021
19
Racial and Ethnic Differences in Metabolic Disease in Adolescents With Obesity and Polycystic Ovary Syndrome. 61
33644620 2021
20
A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. 61
33794784 2021
21
GCSF deficiency attenuates nonalcoholic fatty liver disease through regulating GCSFR-SOCS3-JAK-STAT3 pathway and immune cells infiltration. 61
33470903 2021
22
Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. 61
33534958 2021
23
Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. 61
33368954 2021
24
Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. 61
33586354 2021
25
Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection. 61
33528280 2021
26
Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection. 61
33347957 2021
27
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? 61
32337667 2021
28
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. 61
33497019 2021
29
Modulating effects of the probiotic Lactococcus lactis on the hepatic fibrotic process induced by CCl4 in Wistar rats. 61
33732312 2021
30
Multiparametric in vivo ultrasound shear wave viscoelastography on farm-raised fatty duck livers: human radiology imaging applied to food sciences. 61
33607316 2021
31
The ménage à trois of autophagy, lipid droplets and liver disease. 61
33794741 2021
32
Gut dysbiosis as a driver in alcohol-induced liver injury. 61
33598648 2021
33
Crosstalk between PPARs and gut microbiota in NAFLD. 61
33485064 2021
34
Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis. 61
33665587 2021
35
Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization. 61
33501884 2021
36
Adipose-specific knockout of ubiquitin-conjugating enzyme E2L6 (Ube2l6) reduces diet-induced obesity, insulin resistance, and hepatic steatosis. 61
33712284 2021
37
Serum leptin as a mediator of the influence of insulin resistance on hepatic steatosis in youths with excess adiposity. 61
33618924 2021
38
Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. 61
33406286 2021
39
Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. 61
33606661 2021
40
Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. 61
33773656 2021
41
Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. 61
33482185 2021
42
Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats. 61
33513383 2021
43
A branched-chain amino acid-based metabolic score can predict liver fat in children and adolescents with severe obesity. 61
33058486 2021
44
Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation. 61
33480065 2021
45
A significant association of non-obese non-alcoholic fatty liver disease with osteosarcopenic obesity in females 50 years and older. 61
33745573 2021
46
Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study. 61
33811619 2021
47
Hepatic Ago2 Regulates PPARα for Oxidative Metabolism Linked to Glycemic Control in Obesity and Post Bariatric Surgery. 61
33567453 2021
48
Cardiac magnetic resonance imaging: insights into developmental programming and its consequences for aging. 61
33349289 2021
49
Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection. 61
32991019 2021
50
The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling. 61
33571540 2021

Variations for Non-Alcoholic Fatty Liver Disease

ClinVar genetic disease variations for Non-Alcoholic Fatty Liver Disease:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PRMT7 NM_019023.5(PRMT7):c.1713C>A (p.Cys571Ter) SNV Pathogenic 523434 rs1251713297 GRCh37: 16:68389688-68389688
GRCh38: 16:68355785-68355785
2 PRMT7 NM_019023.5(PRMT7):c.322G>T (p.Glu108Ter) SNV Pathogenic 523435 rs1014959895 GRCh37: 16:68363008-68363008
GRCh38: 16:68329105-68329105
3 YARS1 NM_003680.3:c.806T>C SNV Likely pathogenic 996695 GRCh37: 1:33252555-33252555
GRCh38: 1:32786954-32786954
4 MT-TL1 NC_012920.1:m.3275C>T SNV Uncertain significance 370045 rs1057516057 GRCh37: MT:3275-3275
GRCh38: MT:3275-3275
5 PNPLA3 NM_025225.3(PNPLA3):c.*987_*989dup Duplication Uncertain significance 341961 rs3083314 GRCh37: 22:44343239-44343240
GRCh38: 22:43947359-43947360
6 PNPLA3 NM_025225.3(PNPLA3):c.*989dup Duplication Uncertain significance 341959 rs3083314 GRCh37: 22:44343239-44343240
GRCh38: 22:43947359-43947360
7 OPA1 NM_001354663.2(OPA1):c.-260_-243del Deletion Uncertain significance 214916 rs863224140 GRCh37: 3:193332587-193332604
GRCh38: 3:193614798-193614815
8 PNPLA3 NM_025225.3(PNPLA3):c.*988_*989dup Duplication Likely benign 341960 rs3083314 GRCh37: 22:44343239-44343240
GRCh38: 22:43947359-43947360
9 PNPLA3 NM_025225.3(PNPLA3):c.*691_*692dup Duplication Likely benign 341954 rs397716964 GRCh37: 22:44342941-44342942
GRCh38: 22:43947061-43947062

Cosmic variations for Non-Alcoholic Fatty Liver Disease:

9 (show top 50) (show all 15626)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 36
2 COSM94430614 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 36
3 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 36
4 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 36
5 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 36
6 COSM102741209 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 36
7 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 36
8 COSM103081572 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 36
9 COSM95977701 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 36
10 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 36
11 COSM95960776 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 36
12 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 36
13 COSM99592496 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 36
14 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 36
15 COSM123358576 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.691C>T p.L231= 4:145885684-145885684 36
16 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 36
17 COSM101741672 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 36
18 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 36
19 COSM98561269 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
20 COSM142353152 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
21 COSM142221290 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
22 COSM99854658 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.156G>A p.V52= 19:52002156-52002156 36
23 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
24 COSM141470046 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
25 COSM141819438 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
26 COSM145038099 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
27 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 36
28 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 36
29 COSM140721836 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.2998+205G>A p.? 18:25194955-25194955 36
30 COSM131506983 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 36
31 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 36
32 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 36
33 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 36
34 COSM109096265 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.3433G>T p.V1145L 9:106974156-106974156 36
35 COSM104985080 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.298+23785G>T p.? 2:179745718-179745718 36
36 COSM104427909 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.20G>T p.S7I 2:179745718-179745718 36
37 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 36
38 COSM127708351 ZNF345 liver,NS,carcinoma,hepatocellular carcinoma c.47-856A>T p.? 19:36891962-36891962 36
39 COSM135887725 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1168C>G p.L390V 16:89734008-89734008 36
40 COSM84511025 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 36
41 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 36
42 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 36
43 COSM130415812 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.950C>T p.T317I 12:133010889-133010889 36
44 COSM88697750 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 36
45 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 36
46 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 36
47 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 36
48 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 36
49 COSM113521587 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 36
50 COSM94679661 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 36

Expression for Non-Alcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Non-Alcoholic Fatty Liver Disease.

Pathways for Non-Alcoholic Fatty Liver Disease

Pathways related to Non-Alcoholic Fatty Liver Disease according to KEGG:

36
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.81 MIR34A MIR30A MIR27B MIR27A MIR26A1 MIR21
2 11.06 MIR30A MIR26A1 MIR132

GO Terms for Non-Alcoholic Fatty Liver Disease

Cellular components related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 MIR378A MIR30A MIR27B MIR27A MIR26A1 MIR22
2 extracellular vesicle GO:1903561 9.28 MIR34A MIR30A MIR27B MIR27A MIR26A1 MIR22

Biological processes related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 MIR34A MIR27B MIR21 MIR140 MIR132
2 positive regulation of angiogenesis GO:0045766 9.85 MIR378A MIR30A MIR27B MIR21 MIR132 MIR130A
3 negative regulation of angiogenesis GO:0016525 9.83 MIR34A MIR21 MIR200B
4 transforming growth factor beta receptor signaling pathway GO:0007179 9.81 MIR30A MIR26A1 MIR21
5 cholesterol homeostasis GO:0042632 9.8 MIR34A MIR27B MIR132
6 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.8 MIR27A MIR21 MIR140
7 negative regulation of tumor necrosis factor production GO:0032720 9.79 MIR140 MIR132 MIR130A
8 negative regulation of interleukin-6 production GO:0032715 9.78 MIR26A1 MIR140 MIR132
9 NIK/NF-kappaB signaling GO:0038061 9.77 MIR27B MIR27A MIR130A
10 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.76 MIR27B MIR27A MIR132 MIR10B
11 positive regulation of vascular endothelial cell proliferation GO:1905564 9.73 MIR27A MIR21 MIR132 MIR130A
12 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.72 MIR27B MIR21 MIR132
13 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.72 MIR27B MIR27A MIR26A1 MIR21 MIR130A
14 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.71 MIR378A MIR26A1 MIR140
15 negative regulation of cholesterol efflux GO:0090370 9.71 MIR33A MIR27B MIR27A MIR26A1
16 miRNA mediated inhibition of translation GO:0035278 9.7 MIR378A MIR27B MIR27A MIR21 MIR200B MIR132
17 negative regulation of vascular endothelial growth factor production GO:1904046 9.69 MIR378A MIR34A MIR140
18 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.67 MIR34A MIR21 MIR140
19 positive regulation of cellular senescence GO:2000774 9.65 MIR34A MIR22
20 negative regulation of nitric-oxide synthase activity GO:0051001 9.65 MIR27B MIR26A1 MIR132
21 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.65 MIR27B MIR27A MIR21 MIR132 MIR10B
22 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.64 MIR27B MIR27A
23 positive regulation of lipid storage GO:0010884 9.63 MIR34A MIR10B
24 negative regulation of gene expression GO:0010629 9.61 MSR1 MIR34A MIR33A MIR27B MIR27A MIR21
25 negative regulation of vascular wound healing GO:0061044 9.6 MIR34A MIR200B
26 positive regulation of smooth muscle cell differentiation GO:0051152 9.58 MIR34A MIR22
27 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 MIR27A MIR21
28 regulation of cholesterol esterification GO:0010872 9.57 MIR27B MIR27A
29 negative regulation of monooxygenase activity GO:0032769 9.56 MIR378A MIR27B
30 gene silencing by miRNA GO:0035195 9.53 MIR378A MIR34A MIR33A MIR30A MIR27B MIR27A
31 negative regulation of lipid binding GO:1900131 9.52 MIR27B MIR27A

Molecular functions related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.61 MIR34A MIR30A MIR27B MIR27A MIR21 MIR200B
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR378A MIR34A MIR33A MIR30A MIR27B MIR27A
3 RNA polymerase II complex binding GO:0000993 9.33 MIR378A MIR33A MIR140

Sources for Non-Alcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....